AstraZeneca PLC (LON:AZN) Receives £101.62 Consensus PT from Analysts

AstraZeneca PLC (LON:AZN - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nine brokerages that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is £101.62 ($136.08).

Several brokerages recently weighed in on AZN. Jefferies Financial Group increased their price target on shares of AstraZeneca from GBX 71 ($0.95) to GBX 74 ($0.99) and gave the stock a "hold" rating in a report on Tuesday, July 2nd. JPMorgan Chase & Co. reissued an "overweight" rating on shares of AstraZeneca in a report on Monday, September 16th. Shore Capital restated a "buy" rating on shares of AstraZeneca in a research report on Thursday, July 25th. Berenberg Bank reaffirmed a "buy" rating and set a £150 ($200.86) price target on shares of AstraZeneca in a research report on Monday, September 2nd. Finally, Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and set a £110 ($147.30) price objective on shares of AstraZeneca in a research note on Tuesday, September 3rd.

Insider Transactions at AstraZeneca

In other AstraZeneca news, insider Michel Demare acquired 2,000 shares of the stock in a transaction on Friday, September 13th. The shares were bought at an average cost of GBX 118 ($1.58) per share, with a total value of £2,360 ($3,160.15). Insiders own 0.04% of the company's stock.

AstraZeneca Stock Down 0.6 %

Shares of LON AZN traded down GBX 66 ($0.88) during trading hours on Friday, hitting £116.54 ($156.05). 2,852,079 shares of the stock were exchanged, compared to its average volume of 4,201,670. The company has a market cap of £180.64 billion, a PE ratio of 3,749.92, a PEG ratio of 0.88 and a beta of 0.17. AstraZeneca has a 12 month low of GBX 9,461 ($126.69) and a 12 month high of £133.88 ($179.27). The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 84.97. The firm has a fifty day moving average price of £125.22 and a 200-day moving average price of £119.83.

AstraZeneca Cuts Dividend

The company also recently disclosed a dividend, which was paid on Monday, September 9th. Shareholders of record on Thursday, August 8th were paid a GBX 77.60 ($1.04) dividend. This represents a yield of 0.64%. The ex-dividend date was Thursday, August 8th. AstraZeneca's dividend payout ratio is currently 7,500.00%.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.